Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda/iota in cutaneous angiosarcoma

Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients

(2018) Alexander T. Falk et al.   LUNG CANCER

aPKC controls endothelial growth by modulating c-Myc via FoxO1 DNA-binding ability

(2018) Meghan Riddell et al.   Nature Communications

Survival outcomes for cutaneous angiosarcoma of the scalp versus face

(2017) Jonathan M. Bernstein et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

(2017) Vikram R. Juneja et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

(2017) Zijun Y. Xu-Monette et al.   Frontiers in Immunology

Predisposing factors for poor prognosis of angiosarcoma of the scalp and face: Systematic review and meta-analysis

(2016) Jin Yong Shin et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma

(2016) Yuki Honda et al.   OncoImmunology

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

New immunotherapies targeting the PD-1 pathway

(2015) Jordan M. Chinai et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer

(2013) Aaron S. Mansfield et al.   ANTI-CANCER DRUGS

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

(2013) Taku Okazaki et al.   NATURE IMMUNOLOGY

FOXOs: signalling integrators for homeostasis maintenance

(2013) Astrid Eijkelenboom et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival

(2013) E. J. Lipson et al.   Cancer Immunology Research

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Overall survival and PD-L1 expression in metastasized malignant melanoma

(2010) Jules Gadiot et al.   CANCER

Atypical Protein Kinase C  Expression and Aurothiomalate Sensitivity in Human Lung Cancer Cells

(2008) R. P. Regala et al.   CANCER RESEARCH